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ABSTRACT 
Aortic stenosis has become the most frequent type of valvular heart disease in Europe and North America and 
presents in the large majority of patients as calcified aortic stenosis in adults of advanced age. Surgical aortic 
valve replacement has been recognized to be the definitive therapy which improves considerably survival for 
severe aortic stenosis since more than 40 years. In the most recent period, operative mortality of isolated aortic 
valve replacement for aortic stenosis varies between 1–3% in low-risk patients younger than 70 years and 
between 4 and 8% in selected older adults. Long-term survival following aortic valve replacement is close to that 
observed in a control population of similar age. Numerous observational studies have consistently 
demonstrated that corrective surgery in symptomatic patients is invariably followed by a subjective 
improvement in quality of life and a substantial increase in survival rates.  
More recently, transcatheter aortic valve implantation (TAVI) has been demonstrated to be feasible in patients 
with high surgical risk using either a retrograde transfemoral or transsubclavian approach or an antegrade, 
transapical access. Reported 30-day mortality ranges between 5 and 15%) and is acceptable when compared to 
the risk predicted by the logistic EuroSCORE (varying between 20 and 35%) and the STS Score, although the 
EuroScore has been shown to markedly overestimate the effective operative risk. One major concern remains 
the high rate of paravalvular regurgitation which is observed in up to 85% of the patients and which requires 
further follow-up and critical evaluation. In addition, long-term durability of these valves with a focus on the 
effects of crimping remains to be addressed, although 3-5 year results are promising. 
Sutureless biological valves were designed to simplify and significantly accelerate the surgical replacement of a 
diseased valve and allow complete excision of the calcified native valve. Until now, there are 3 different 
sutureless prostheses that have been approved. The 3f Enable valve from ATS-Medtronic received CE market 
approval in 2010, the Perceval S from Sorin during Q1 of 2011 and the intuity sutureless prosthesis from 
Edwards in 2012. All these devices aim to facilitate valve surgery and therefore have the potential to decrease 
the invasivness and to shorten the conventional procedure without compromise in term of excision of the 
diseased valve. This review summarizes the history and the current knowledge of sutureless valve technology. 
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TREATMENT OF VALVULAR AORTIC 
STENOSIS 
 Aortic stenosis has become the most 
frequent type of valvular heart disease in Europe 
and North America and presents in the large 
majority of patients as calcified aortic stenosis in 
adults of advanced age (2–7% of the population 
aged more than 65 years) [1-4]. The second most 
frequent reason for aortic stenosis is of 
congenital origin in the younger age group, 
whereas rheumatic aortic stenosis has become 
rare but still present in developing countries.  
 Echocardiography has become the 
principal diagnostic examination method and 
easily allows to confirm the presence of valvular 
aortic stenosis, to assess the degree of valve 
calcification, the function, the size and the wall 
tickness of the left ventricle. A valve area <1.0 
cm2 is considered as severe aortic stenosis, but 
indexing this value to body surface area, with a 
cut-off value of  < 0.6 cm2/m2 body surface area 
is helpful, in particular in patients with unusually 
small or large body surface. Computed 
tomography and magnetic resonance imaging 
allow complete assessment of the thoracic aorta 
(root, ascending, arch and descending 
segments). In patients over age of 40 years, 
cardiac catheterism allows to assess invasively 
transvalvular pressure gradients and 
hemodynamic conditions whereas coronary 
angiography gives important informations about 
the coronary arteries. Valvular aortic stenosis is 
a chronic progressive disease. The patients may 
remain asymptomatic during a long time and 
sudden cardiac death may happen in 
symptomatic patients [5-7]. Early valve 
replacement should be strongly recommended 
in all symptomatic patients with severe aortic 
stenosis who are considered to be candidates for 
surgery. As long as the mean gradient remains 
above > 40 mmHg, there is virtually no lower EF 
limit for surgery. 
 Surgical aortic valve replacement has been 
recognized to be the definitive therapy (which 
improves considerably survival) for severe aortic 
stenosis since more than 40 years. In the most 
recent period, operative mortality of isolated 
aortic valve replacement for aortic stenosis 
varies between 1–3% in low-risk patients 
younger than 70 years and between 4 and  8% in 
selected older adults [2, 8, 9]. The following 
factors have been recognized to increase 
significantly the risk of surgery: older age, 
associated comorbidities, female gender, higher 
NYHA functional class, emergency operation, 
left-ventricular dysfunction, pulmonary 
hypertension, coexisting coronary disease, and 
redo-intervention. Long-term survival following 
aortic valve replacement is close to that 
observed in a control population of similar age. 
Numerous observational studies have 
consistently demonstrated that corrective 
surgery in symptomatic patients is invariably 
followed by a subjective improvement in quality 
of life and a substantial increase in survival rates. 
In addition, AVR may also provide survival 
benefit for selected asymptomatic patients, 
when compared to conservative management 
[10-16]. The 2012 update of the ESC/EACTS 
Guidelines for the management of patients with 
valvular heart disease also states that aortic 
valve replacement may be considered for 
asymptomatic patients with severe aortic 
stenosis and abnormal response to exercise [17]. 
 Several considerations must be addressed 
whenever surgical correction of aortic stenosis is 
warranted, such as the choice of a mechanical 
valve versus the use of a bioprosthetic valve, 
including stented and stentless valves, aortic 
homografts, cadaveric recovered autografts. 
While mechanical valves are more durable in 
general, bioprosthetic valves and do not require 
lifelong anticoagulation. Stentless bioprosthetic 
valves were first introduced in the 1990`s and 
are reported to have superior hemodynamic 
properties comparing to stented valves due to 
lower pressure gradients and reduced 
turbulence in the aortic sinuses. This ensures 
superior coronary circulation during diastole 
[18].  
 More recently, transcatheter aortic valve 
implantation (TAVI) has been demonstrated to 
be feasible in patients with high surgical risk 
using either a retrograde transfemoral 
transsubclavian or direct aortic approach or an 
antegrade, transapical access [19-26]. Reported 
30-day mortality ranges between 5 and 15% and 
is acceptable when compared to the risk 
predicted by the logistic EuroSCORE (varying 
between 20 and 35%) and the STS Score, 
although the EuroScore has been shown to 
markedly overestimate the effective operative 
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risk [27]. One major concern remains the high 
rate of paravalvular regurgitation which is 
observed in up to 85% of the patients and which 
requires further follow-up and critical 
evaluation. In addition, long-term durability of 
these valves with a focus on the effects of 
crimping remains to be addressed, although 3-5 
year results are promising [26]. 
 In addition, the occurence of paravalvular 
regurgitation in TAVI has been shown to be 
predictive for mid-term survival [28]. 
 Management of asymptomatic severe 
aortic stenosis remains a matter of controversy 
[29-31]. The decision to operate on 
asymptomatic patients requires careful weighing 
of benefits against risks. Watchful waiting 
appears particularly safe and the benefit of early 
surgery seems highly unlikely in patients with  
normal exercise tests and normal/low natriuretic 
peptide levels. Early elective surgery should only 
be considered in selected patients at low 
operative risk with one or more of the following 
situations: 1) Depressed LV function not due to 
other causes, 2) Combination of a markedly 
calcified valve with a rapid increase in peak 
transvalvular velocity of ≥ 0.3 m/s per year, 3) 
Abnormal exercise test, particularly one with 
symptom development or fall of blood pressure 
below baseline, 4) Severly elevated natriuretic 
peptide levels confirmed by repeated 
measurements without other explanations, 5) 
Excessive LV hypertrophy without history of 
hypertension and 6) Very severe AS defined by a 
peak velocity >5-5.5m/s and 7) Increase of mean 
pressure gradient with exercise by >20mmHg 
[32]. 
CHOICE OF THE PROSTHETIC VALVE 
WITH SPECIAL EMPHASISIS ON 
SUTURELESS VALVE TECHNOLOGY 
 In 1954, Hufnagel and colleagues 
described 23 patients with aortic insufficiency 
who had been treated during the previous 2 
years by rapid insertion of an acrylic ball valve 
into the descending aorta [33]. Since the valve 
prevented regurgitant flow only from the low 
part of the body, cardiac work was only partially 
decreased. In addition, embolization and 
thrombosis of the valve appeared quite often. In 
September 1960, Starr performed the first 
successful mitral valve replacement using a 
caged ball valve [34]. 
 At that time, pioneer surgeons recognized 
that the ideal valve shoud be chemically inert, 
compatible with human tissues, atraumatic to 
blood cells and nonthrombogenic. In addition 
they looked for a prosthesis to be implanted 
securely in a physiologic position. With further 
development in mechanical prostheses (tilting 
disk, bileaflet valve), and major advances in the 
field of biological prostheses, valve replacement 
surgery improved considerably the natural 
history of patients with mitral and aortic stenosis 
and regurgitation [35]. Despite major advances 
in technologies, there are still no perfect valve 
substitutes. Whether mechanical or biological, 
all prosthetic valves have some advantages but 
also some inconvenients for the patients. The 
most recent bileaflet and tilting-disk mechanical 
valves have the theoretical advantage of long-
term absence of any structural degeneration but 
they require lifelong anticoagulation. In contrast, 
all tissue valves (including homografts, 
pulmonary autografts, as well as porcine and 
pericardial bovine or equine bioprostheses) do 
not require long-term anticoagulation, but they 
are all subject to structural valve deterioration 
over time.  Biological valves can be further 
subdivided into stented and stentless. The 
design of the stentless valves was intended to 
provide a better effective valve area. More 
favourable haemodynamics have been reported, 
but no improvement in long-term durability has 
been demonstrated so far. Sutureless valves are 
an incoming technology that allows quick 
placement of a bioprosthesis without a sewing 
cuff. This technology will be presented hereafter 
with more details. 
 In practice, the choice is between a 
mechanical prosthesis and a bioprosthesis in the 
majority of patients. The heterogeneity of 
valvular heart diseases and the variability of 
outcome of complex procedures make the 
design and the execution of prospective 
randomised trials difficult. Two historical 
randomized trials comparing older models of 
mechanical and bioprosthetic valves found no 
significant difference in rates of valve 
thrombosis and thromboembolism, in 
accordance with numerous individual valve 
series. Long-term survival was very similar [36, 
37]. A more recent trial randomised 310 patients 
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aged 55 to 70 to mechanical or biological 
prosthesis [38]. No differences were found in 
survival, thromboembolism, and bleeding rates 
but – as expected - a higher rate of valve failure 
and reoperation following implantation of 
bioprostheses. The choice between a mechanical 
valve and a bioprosthesis in adult patients is 
mainly determined by assessing the risk of 
anticoagulant-related bleeding and 
thromboembolism with a mechanical valve 
versus the risk of valve degeneration with a 
bioprosthesis and by considering the patient’s 
goals, values and preferences for life and 
healthcare [39-42]. 
 Rather than setting arbitrary age limits, 
prosthesis choice is usually considered on an 
individual basis and discussed in detail with the 
patient, taking into account the following: 
bioprostheses should be considered in patients 
whose life expectancy is lower than the 
presumed durability of the bioprosthesis, 
particularly if comorbidities will necessitate 
other surgical procedures in the future, and in 
those with increased bleeding risk. Although 
structural valve degeneration is accelerated in 
chronic renal failure, poor long-term survival 
with either type of prosthesis, and an increased 
risk of complications with mechanical valves, 
may favour the choice of a bioprosthesis in this 
situation [43]. Quality of life issues and informed 
patient preferences must also be taken into 
account. Inconvenience of oral anticoagulation 
can be minimised by self-management of 
anticoagulation [44]. Although bioprosthetic 
recipients can avoid long-term anticoagulation, 
they face the possibility of deterioration of their 
clinical condition due to degeneration of the 
bioprosthesis and the prospect of reoperation if 
they live long enough. During mid-term follow-
up certain patients receiving a bioprosthetic 
valve may develop another condition requiring 
oral anticoagulation (atrial fibrillation, stroke, 
peripheral arterial disease and other).  
CURRENT EXPERIENCE WITH 
SUTURELESS VALVES 
 The concept of sutureless valve was 
already tested in the early sixties [45], with the 
idea to facilitate implantation and shorten 
ischemic and perfusion times. However, the 
concept was abandoned due to multiple 
complications, such as paravalvular leakage and 
valve-related thromboembolic events. Recently, 
sutureless aortic valve implantation has received 
increasing interest, due to the rapid 
development of transcatheter valve technology. 
Shortening the time required for aortic valve 
replacement may help to reduce the morbidity 
and mortality, especially in patients who require 
complex multivalve or combined valve and 
coronary procedures. 
 Sutureless biological valves were designed 
to simplify and significantly accelerate the 
surgical replacement of a diseased valve and 
require first complete excision of the calcified 
native valve. Until now, there are 3 different 
sutureless prostheses that have been approved. 
The 3f Enable valve from ATS-Medtronic 
received CE market approval in 2010, the 
Perceval S from Sorin during Q1 of 2011 and the 
Intuity sutureless prosthesis from Edwards most 
recently in 2012 entered pilot clinical 
investigation. There are to date more than 40 
patents with respect to sutureless valve 
technologies. 
THE ENABLE VALVE FROM ATS-
MEDTRONIC 
 The Enable valve combines the 
characteristics of the 3f stentless valve to a 
nitinol stent which unfolds at normal 
temperature. To better understand the concept 
of the 3f-Enable valve, a short summary on the 
original stentless valve and the clinical results 
will be given first.   
THE 3F STENTLESS VALVE FROM ATS 
 The ATS-Medtronic 3f® Aortic 
Bioprosthesis Model 1000 is a stentless 
bioprosthesis with excellent mechanical 
properties and performance characteristics. It 
was designed with the aim to mimic the 
physiological function of the native aortic valve 
as closely as possible. It is known from human 
embryonic studies that the primary structure of 
the aortic valve is tubular and adopts its shape 
to the hemodynamic forces during the cardiac 
cycle when fully developed, thus ensuring 
unidirectional blood flow. The ATS 3f valve was 
designed with these anatomical functional 
properties in mind (3f - form follows function). 
Open Journal of Cardiology, 2013, 4-1    
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Figure 1. Tubular structure of the stentless 3-f aortic 
tissue valve 
 The valve structure is assembled together 
from three equal sections of glutaraldehyde-
fixed equine pericardial tissue. Glutaraldehyde is 
used to preserve the collagen matrix of the 
pericardium and to reduce its immunogenic and 
thrombogenic potentials while preserving its 
strength and flexibility. A thin sewing ring is 
added to the proximal orifice of the 
bioprosthesis to be attached to the aortic root 
orifice after dissection of the native, diseased 
valve. The distal portion of the valve has three 
commissural tabs that are attached to the aortic 
wall using locking sutures. The above design 
allows the 3f valve to closely mimic the function 
of the native aortic valves.  
 The anatomic design of the valve is 
emphasized by the fact that it appears very 
similar than the native aortic valve both visually 
and in functionality on echocardiography.  In 
addition, salient features of this “cuspal” 
replacement include: 1) Absence of animal 
arterial wall (seen with porcine bioprostheses 
that may fuse to the native aortic wall by 
calcification within 5 years of implantation); 2) 
Preservation of the aorto-ventricular junction 
and the sino-tubular junction continuity thus 
retaining the function of the sinuses of Valsalva; 
3) Restoration of native valve stress distribution; 
4) Improved coronary artery blood flow during 
diastole minimizing myocardial ischemia; 5) 
Restored physiological blood flow without areas 
of stagnation. 
 The Medtronic-ATS 3f® Aortic 
Bioprosthesis Model 1000 has been tested 
extensively per the US Food and Drug 
Administration (FDA) and International 
Standards Organization (ISO) guidelines in the 
pre-clinical stage. Results of the in vitro and in 
vivo studies were favorable compared to 
controls of commercially available stentless and 
stented valves. Subsequently, a clinical 
investigation protocol was developed with the 
goal to enroll patients presenting with severe 
aortic stenosis or combined lesions of aortic 
stenosis and insufficiency. It is the objective of 
the following section to present the mid-term 
results of a subset of investigational sites 
participating in a multicenter, prospective 
clinical study with the 3f® Aortic Bioprosthesis 
Model 1000 [46]. 
CLINICAL EXPERIENCE WITH THE 3F- 
STENTLESS IN THE PROSPECTIVE 
MULTICENTRIC STUDY  
One hundred and sixty five patients (109 
males, 56 females, average age: 67.8±12.7 years) 
were implanted with the 3f valve as part of a 
prospective, international, multicenter, non 
randomized study at 4 investigational sites. 
Valve replacement surgeries were performed 
between 2001 and 2004. Patients requiring 
isolated aortic valve replacement with or 
without concomitant procedures, except for 
mitral, pulmonary or tricuspid valve 
replacement, and with average or better 
operative risk were eligible to participate. 
Exclusion criteria included age below 20 years, 
life expectancy of 12 months or less, congenital 
bicuspid aortic anatomy and previously 
implanted prosthetic heart valve that is not 
being replaced by the study valve.  Subjects not 
agreeable to return to the implant centre for the 
required number of follow up visits and those 
who participated in concomitant research 
studies of investigational products were also 
excluded.  
 The indication for the aortic valve 
replacement was degenerative (69.1%), 
rheumatic (27.7%), congenital (7.4%), and 
previous endocarditis-related (0.6%) aortic valve 
pathology. Notably, 4.8% of patients had more 
than one indication for the surgery, such as 
degenerative disease due to congenital aortic 
valve anomaly. Transesophageal 
echocardiography was performed 
intraoperatively to verify correct valve 
positioning and to assess for paravalvular leak. 
Patients were followed prospectively for 
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3.07±1.50 years (506.74 patient years) at 
regularly scheduled visits. In addition to routine 
physical examination and chemistry panel, 
transthoracic echocardiogram was performed at 
hospital discharge, at 3 and 6 months post-
surgery and annually thereafter. TEE and TTE 
images were forwarded to an independent 
echocardiographic core laboratory for data 
analysis. All adverse events were recorded and 
analyzed in accordance with regulatory 
requirements. Early adverse events were defined 
as complications occurring within the first 30 
days post-implantation. All subsequent 
complications were categorized as late adverse 
events. The study was conducted according to 
the applicable local and international regulatory 
requirements and was approved by the local 
ethics committee at each institution. 
 
 
Figure 2. (left) Native valve form and function is reproduced resulting in minimal stresses at the commissures and 
more evenly distributed stresses throughout the leaflet. (right) 3-f tissue valve in the native aortic root: note the large 
coaptation line. 
 
 Prosthetic valves with the following size 
distribution were implanted: 21mm (7.4%), 
23mm (28.4%), 25mm (25.9%), 27mm (19.8%), 
and 29mm (18.5%). Five patients (3.0%) died 
within the immediate perioperative period; 1 
due to valve-related while 4 due to non valve 
related causes. The cause of death was 
fulminant sepsis in 2 patients; cerebral 
thromboembolism in 1 subject, acute myocardial 
infarction in 1 patient and acute systolic heart 
failure with concomitant multiorgan failure in 1 
subject. Early non-fatal complications were 
limited to ischemic cerebrovascular events in 3 
patients (1.8%). As demonstrated on Figure 1, 
valve-related mortality was very low during the 
study period (cumulative freedom from valve-
related mortality is 98.5% after five years of 
follow-up). 
 
Figure 3. Cumulative freedom of valve-related and 
overall mortality 
 A late adverse event was recorded in 23 
patients (4.5% /patient year) during the five 
years follow-up period. 13 participants (2.57% 
/patient year) suffered a thromboembolic event: 
1 pulmonary embolism and 12 cerebrovascular 
events were reported, 5 of these were 
consistent with transient neurological deficit. 
Endocarditis was documented in 4 patients 
(0.79% /patient year), all of which resulted in 
valve explantation. In addition, valve 
explantation was necessary in 2 cases (0.4% 
/patient year) due to echocardiographic 
Open Journal of Cardiology, 2013, 4-1    
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evidence of paravalvular leak. No structural 
prosthetic deterioration or valve thrombosis 
occurred during the five years follow up. 
 
Figure 4. Cumulative freedom from adverse events. 
 Hemodynamic parameters, as assessed 
with TTE at the time of hospital discharge, at 12 
and 36 months post-surgery are listed in Ta. 
Notably, the mean aortic gradient was measured 
at 12.1 mmHg at discharge and at 9.4 mmHg at 
36 months with the difference reaching 
statistical significance. In accordance, peak aortic 
gradient decreased from 21.8 to 17.5 mmHg by 
the third postoperative year with the reduction 
again being statistically significant. The effective 
orifice area (1.9 ± 0.7 at discharge and 2.0 ± 0.7 
cm2 at 3 years), indexed effective orifice area 
(1.0 ± 0.4 at discharge and 1.0 ± 0.3 cm2/m2 at 3 
years), cardiac output (5.3 ± 1.5 at discharge and 
5.1 ± 1.3 L/min at 3 years) and cardiac index (2.8 
± 0.8 at discharge and 2.7 ± 0.6 L/min/m2 at 3 
years) were sustained during the follow-up 
period (Table 1 below). 
Table 1. Postoperative haemodynamic parameters 
 Discharge n Post implantation p* 
1 year n 3 years n 
Mean gradient (mmHg) 12.1 ± 6.5 148 11.2 ± 5.1 127 9.4 ± 4.0 75 0.0045 
Peak gradient (mmHg) 21.8 ± 11.3 148 19.7 ± 8.5 127 17.5 ± 7.2 75 0.0251 
Effective orifice area (cm
2
) 1.9 ± 0.7 106 1.9 ± 0.7 100 2.0 ± 0.7 55 0.6089 
Indexed effective orifice area 
(cm
2
/m
2
) 
1.0 ± 0.4 100 1.0 ± 0.3 90 1.0 ± 0.3 55 0.7640 
Left ventricular cardiac output 
(L/min) 
5.3 ± 1.5 112 5.1 ± 1.4 103 5.1 ± 1.3 57 0.1279 
Left ventricular cardiac index 
(L/min/m
2)
 
2.8 ± 0.8 107 2.7 ± 0.7 94 2.7 ± 0.6 57 0.1546 
 
 The valve proved to be versatile and has 
shown superior intraoperative handling 
characteristics. Despite reports indicating that 
stentless aortic valves generally require a more 
complex surgical approach than stented valves, 
they indeed carry a similar operative risk. As an 
added advantage for the surgeons, this unique 
valve requires only one circumferential suture 
line at the inflow side thereby saving operative 
time and allowing less complicated implantation 
procedure [47-49]. As such, no lengthy learning 
curve or major inter individual differences were 
observed among surgeons at different sites with 
regards to aortic cross-clamp times and 
procedural complications. In addition to the 
good hemodynamic profile, the valve has 
demonstrated a safe clinical profile in this 
patient cohort. Early fatal complications were 
limited to 3% including one valve-related death 
(0.6%) and 4 non valve related fatalities (2.4%). 
Non-fatal complications were documented in 
1.8% of patients. Late adverse events were 
recorded in 4.5% /patient-year during the 
follow-up period, including thromboembolic 
events, endocarditis and paravalvular leak. No 
structural prosthetic deterioration or valve 
thrombosis occurred during the entire study 
period. Cumulative freedom from valve-related 
mortality was 98.5% after five years of follow-
up. Overall, the adverse event rate with the ATS 
3f® Aortic Bioprosthesis was comparable to 
those observed with other commercially 
available stentless aortic valves. However, no 
structural valve deterioration was detected in 
the present study. Indeed, in vitro tests 
indicated the superior durability of the valve 
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when compared to test devices, most likely due 
to the improved leaflet stresses. Continued 
clinical follow up continues to document the 
long-term performance, durability and safety 
profile of this unique bioprosthesis. 
ENABLE I DEVICE DESCRIPTION 
 The 3f Enable® Aortic Bioprosthesis Model 
6000, was developed for aortic valve 
replacement.  Like in the 3f tissue valve, the 
valve leaflets are designed to simulate the 
tubular nature of valvular development in utero. 
The device consists of the following: a 3f Aortic 
Bioprosthesis Model 1000 assembled from three 
equal sections of equine pericardial material that 
have been cross-linked with formulations of low 
concentration glutaraldehyde under specific 
parameters of time, pH and temperature. This 
fixation process preserves the collagen 
architecture of the pericardial material, 
minimizes the immunogenic potential of the 
xenogeneic tissue, and preserves flexibility and 
strength. The valve has been introduced in a self-
expanding Nitinol frame. A polyester fabric 
covers the inflow flange/skirt (Figure 5). 
 
Figure 5. 3f stentless valve Model 1000 (top left) and 
Nitinol Frame (top right)   
The 3f Enable® Aortic Bioprosthesis Model 6000 
(bottom) 
 The design concept of the Model 6000 
valve are three equal equine pericardial leaflets 
that are assembled into a tubular structure, and 
result in three equispaced commissural tabs of 
special design just like the Model 1000.  These 
tabs are reinforced with equal sections of 
polyester material and are fixed into specially 
designed commissural tab attachment eyelets in 
the superior aspect of the NiTiNOL frame.  The 
self-expanding NiTiNOL frame contributes partly 
to the fixation of the device, in the deployed 
location, by virtue of outwardly emitted, radial 
forces inherent in the NiTiNOL material (chronic 
outward force).  This allows for the use of the 
only one guiding stitch to correct placement of 
the valve to the annulus.  Further contributions 
to fixation into the aortic root are provided by 
the polyester fabric covering on the inflow 
aspect of the device. The polyester flange has 
been incorporated at the inflow aspect to 
minimize the potential of perivalvular leaks and 
migration, and apposes well to the aortic 
annulus without blocking the coronary ostia. The 
Model 6000 has a polyacetal homopolymer 
folding sleeve that is attached to the valve and is 
used in conjunction with an accessory inserter 
system to aid in folding and insertion of the 
valve.   
 The Model 6000 bioprosthesis is supplied 
in diameters of: 19 mm, 21mm, 23mm, 25mm, 
27mm and 29mm.  These sizes correspond to the 
orifice created by removal of the diseased valve 
from the aortic root and can be measured with 
the obturators supplied. The picture of the 
Model 6000, Enable valve, identifies the “flange” 
of the valve.  The inflow of the valve has a 
portion that is covered with polyester material.  
We refer to this section of the valve as the 
"flange".  The Enable valve is a sutureless valve, 
thus, there is no sewing ring attached to the 
valve.  Inadvertently, people have referred to 
this section of the valve as the flange, inflow 
flange, skirt, or even "sewing ring"; however, 
these are the same part of the valve. 
 The scalloped polyester flange conforms to 
the aortic annulus of the patient. The scalloped 
flange is 2 mm in thickness and should be 
positioned approximately 1 mm above or on the 
aortic annulus (i.e., supra-annularly). The pliable 
nitinol-stent allows for crimping the valve at low 
temperatures at about 5°C. The stent regains its 
original shape at room temperature due to the 
memory effect of the nitinol.  
OWN EXPERIENCE 
 Outcome analysis of a consecutive series 
of 28 patients who underwent  aortic valve 
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replacement (AVR) for aortic stenosis with the 
ATS 3f-Enable™ during a 18 months-period. The 
study was approved by the institutional review 
board of Berne University Hospital and all 
patients gave written informed consent. Mean 
age of the patients was 75.7±6.6 years, 18 were 
female (64.2%). Mean Euro-Score was 7.1±1.7. 
The majority of implanted valves was 23mm in 
diameter (range: 19-27mm). Mean aortic cross-
clamping time was 39±15 min (range: 29-103 
min) and mean cardiopulmonary bypass time 
was 58±20 min (range: 41-127). No 
intraoperative complications, such as valve 
migration, coronary ostia obstruction, mitral 
regurgitation or injury to the ascending aorta 
occurred in this series.  
 Three patients were found to have 
paravalvular leakage because of insufficient 
valve expansion; in 2 cases the valve implanted 
was too large and the Nitinol-stent could not 
fully expand. In these cases, the next smaller 
valve was implanted without difficulty. In one 
patient, the surgeon decided to proceed with a 
stented bioprosthesis. 
 Mean length of hospital stay was 11 days 
[7-22]. 30 day-mortality rate was 3.5%. Mean 
and peak intraoperative transvalvular pressure 
gradients were respectively 6.1±2.6 mmHg and 
18±5mmHg. Trivial and mild paravalvular leak 
was observed in one patient each. One patient 
underwent redo-AVR 4 months after initial 
surgery due to severe valve-unrelated 
paravalvular leakage. 5 patients (18.5%) required 
permanent pacemaker. Postoperative 
anticoagulation consisted in acetylsalicylic acid 
100 mg. Oral anticoagulation was administred 
only in presence of any additional risk factor 
(atrial fibrillation, ejection fraction below 30%). 
Follow-up consisted of clinical examinations as 
well as intra- and postoperative 
echocardiography (at discharge, 6 and 12 
months).  
 Main exclusion criteria were: patients with 
previous cardiac surgery, dilated (> 4 cm) and 
severly calcified ascending aorta and aortic root, 
as well as active endocarditis. Combined AVR 
and myocardial revascularization was not an 
exclusion criterium. One patient developed 
significant leakage after 3 months. One month 
later, the Enable valve was replaced with a 
biological stented valve. Explantation of the 
valve was very easy; the valve was intact (Figure 
6). The reason for leakage was valve-unrelated. 
A localized detachment of the anterior mitral 
valve leaflet was found to be related to deep 
decalcification of the native aortic annulus. 
Discordance between the sinotubular ridge and 
diameter of the aortic annulus is not of concern 
for this type of valve, since fixation occurs only 
at the level of the annulus. No patient was lost 
from follow-up and 1-year survival was 86.2%. 
The procedure was fast but not as short as 
expected. This experience has lead to major 
modifications of the design, which will facilitate 
and accelerate implantation. 
 
Figure 6. Explanted Enable valve because of 
paravalvular leak: no structural changes of the valve 
were noted. 
IMPLANTATION TECHNIQUE 
 Surgery is performed under full 
sternotomy or mini-sternotomy. Standard 
cardiopulmonary bypass (CPB) was established 
by cannulation of the ascending aorta and the 
right atrium. Myocardial protection was 
achieved by 100 ml antegrade crystalloid single-
shot cardioplegia (Cardioplexol®, Bichsel 
Laboratory, Interlaken, Switzerland). Transverse 
aortotomy was performed approximatively 2 cm 
above the commissures. The valve was excised 
and the annulus decalcified as for conventional 
AVR.  
 Sizing of the prosthesis is a crucial step 
since neither over- nor undersizing is 
recommendable, because the sizes of the device 
are really true sizes and it is not possible to 
expand an oversized Enable valve in a smaller 
annulus. Following usual rinsing (3 times 30 
sec.), the valve is merged in ice-sludge to allow 
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the folding (Figure 7) and insertion of the 
stented valve into the applicator (Figure 8). If 
necessary a guiding stitch is placed at the level of 
the lowest point of the native annulus in one of 
the intracommissural trigones (preferably at the 
left - non-coronary commissure), to avoid 
rotation or to deep insertion of the valve. The 
stitch is passed through the suture ring of the 
valve and the prosthesis is pushed out of the 
applicator. Expansion of the nitinol stented valve 
is performed under constant observation using 
warm saline solution. The tabs are not sutured 
to the aortic wall but attached to the stent; they 
come in contact with the aortic wall after 
expansion of the valve (Figure 9). Inspection of 
the coronary ostia is very easy due to the intra-
annular position of the valve. The aortotomy is 
closed with a running suture and the operation 
terminated in the usual way. Position and 
function of the valve were assessed by 
intraoperative TEE immediately after weaning 
from CPB. 
 
Figure 7. Folding of the valve in iced solution 
 
Figure 8. Introduction of the folded valve in the 
delivery device 
 
Figure 9. Intraoperative situs following deployment of 
the valve, immediately before closure of aortotomy 
THE PERCEVAL S SUTURELESS VALVE 
 Perceval S is a prosthetic valve comprising 
a bovine pericardium tissue valve attached to a 
self-expandable anchoring device, which has the 
dual role of supporting the valve and providing 
fixation to the implantation site (Figure 10). The 
anchoring device design is characterized by two 
ring segments (outflow and inflow ring), three 
commissural elements supporting the valve, and 
three pairs of sinusoidal elements providing 
fixation in the sinuses of Valsalva. The material 
used for the anchoring device is an equiatomic 
alloy of Nickel and Titanium called Nitinol, able 
to bear large recoverable deformation 
(approximately 8 to 10 times that of steel), 
regaining its initial shape when stress is removed 
(deformation-driven Superelastic effect). 
Therefore, the Perceval S prosthesis can be 
compressed for the implantation and is able to 
reach its final diameter when released. 
 
Figure 10. Stentless Solo tissue valve (top left). 
Anchoring device (top right) and the Perceval S 
sutureless valve (bottom). 
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 The anchoring device is coated with 
CarbofilmTM, a thin turbostratic carbon film 
which improves material haemo- and 
biocompatibility. The tissue valve is 
manufactured as any other Sorin (Saluggia, Italy) 
bovine pericardial valve: the clinically proven 
double-sheet pericardium valve design is 
completed by a pericardial sealing collar 
encouraging adaptation to the aortic annulus 
and preventing paravalvular leakage [50]. In 
correspondence to each valve sinus a button 
hole is provided on the inflow ring, through 
which temporary guide threads are passed to aid 
prosthesis positioning. The bovine pericardial 
tissue used for Perceval S is stabilised using a 
clinically proven glutaraldehyde fixation process, 
followed by a proprietary aldehyde residues 
neutralization treatment which allows to avoid 
rinsing. 
 The prosthetic implant is supported by 
dedicated tools: crimping system, manometer 
and dilatation balloon (Figure 11). In fact, prior 
to implantation the prosthesis diameter is 
reduced to a suitable size, using the Perceval S 
collapsing tool, and then loaded on the Perceval 
S holder (Figure 12). After in situ positioning the 
valve is released in two steps: first the inflow 
ring is released at the annulus level and then, 
when proper positioning is verified, the 
complete prosthesis release is achieved. 
Following implant Perceval S post-dilation 
balloon catheter is inflated inside the prosthesis 
at the inflow level to improve apposition by 
modeling the inflow ring on the annulus. 
Perceval S bendable dual ended sizers assist the 
physician in choosing the proper prosthesis size: 
their design allows visibility of the annulus, fits 
also with complex anatomy and helps obtaining 
an ideal positioning with respect to the 
commissures. 
 
Figure 11. Crimping instrument and balloon catheter for the deployment perceval valve. 
 In vitro accelerated fatigue tests were 
performed under normal and hypertensive 
conditions, demonstrating that the whole 
prosthesis remains functional up to 900 Million 
cycles (more than 20 year of equivalent life). 
These outstanding results exceed the minimal 
ISO and FDA requirements and suggest a wide 
safety margin of the Perceval S prosthesis. 
At the present time, the Perceval S prosthesis 
has been investigated in three clinical studies:  
1. the “PERCEVAL TRIAL – Perceval S valve pilot 
trial – V10601”,  
2. the “PERCEVAL Pivotal Trial – V10801” and  
3. the “CAVALIER - Perceval S valve clinical trial 
for extended CE mark – TPS001”.  
 The pilot trial was aimed at demonstrating 
the 30-days safety of the Perceval S valve in 30 
high risk patients requiring aortic valve 
replacement due to stenosis or steno-
insufficiency. This prospective and non-
randomised study was conducted at 3 European 
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Investigational Centres between April 2007 and 
February 2008. The valve size range comprised 
21 and 23 sizes and the target patients were high 
risk population for surgical procedure (e.g. 
subjects older than 75 years, with NYHA class III 
and IV, Logistic EuroSCORE >5%, without aortic 
dilatation). The valve was implanted following 
sternotomy, extracorporeal circulation (ECC), 
aortic cross-clamping, cardioplegic arrest, and 
removal of the native valve. Implantation 
suturing was not required. Optimal annular 
sealing was obtained with brief low-pressure 
balloon dilation. If coronary bypass was 
indicated, a distal anastomosis was performed 
first. Between April 2007 and February 2008, 30 
patients (mean age: 81 +/- 4 years) underwent 
aortic valve replacement. With this device in our 
institution the prevalence of pure aortic stenosis 
was 76.7%, and that of mixed lesion 23.3%. The 
mean logistic EuroSCORE was 13.18%, and the 
NYHA class was III and IV in 93.3% and 6.7% of 
patients, respectively. The implanted valve size 
was 21 and 23 mm in 37% and 63% of patients, 
respectively, and 14 (46.7%) underwent 
coronary artery bypass grafting (11 internal 
mammary arteries, nine vein grafts). The mean 
aortic cross-clamp and ECC times were 34 +/- 15 
min and 59 +/- 21 min, respectively. There was 
one in-hospital death (3.3%), and three deaths 
occurred within 12 months of follow up (one 
death was valve-related, and two deaths were 
independent of the valve implantation). The 
patients underwent to clinical and 
echocardiographic follow-up at discharge, 1, 3, 6 
and 12 months after implant and then annually 
A total of 28 patients was assessed at one month 
post-implantation, and 23 after 12 months. No 
migration or dislodgement of the valve had 
occurred, but there were two mild paravalvular 
leakages and two mild intravalvular 
insufficiencies. The preliminary results of the 
trial confirmed the safety and efficacy of the 
Perceval S sutureless aortic valve. In this high-
risk subset of patients, shortening the aortic 
cross-clamp and ECC times may help to reduce 
mortality and morbidity [51, 52, 53]. 
 Based on the Pilot results, Sorin Biomedica 
Cardio S.r.l. designed the “PERCEVAL Pivotal Trial 
– V10801” aimed at confirming the safety and 
performance results of the first trial in a larger 
patient population and obtaining the CE mark 
with limited indication. In particular, the valve 
size range comprised 21, 23 and 25 mm sizes 
and the target patient population was the one at 
high risk for surgical procedure of the first study 
(e.g. subjects older than 75 years, with NYHA 
class III and IV, Logistic EuroSCORE >5%, without 
aortic dilatation). In the Pivotal trial 150 patients 
were enrolled in 9 European Investigational 
Centers between January 2009 and January 
2010. The primary endpoint was the evaluation 
of the safety and the performance (in terms of 
improvement of clinical status and 
hemodynamic performance) of the Perceval S 
prosthesis at 3-6 months after implant. The 
secondary endpoints were the assessment of 
mortality and morbidity rates and of the 
performance at discharge (or 30 days if the 
patient is still hospitalized) and 12 months after 
implant. 
 Folliguet reported recently the results of a 
series of 208 high-risk patients operated in 2 
European Centers [51]. Median follow up was 10 
± 20 months and the total accumulated follow-
up was 156 patient-years. Mean cross-clamp 
time and extracorporeal circulation time were 33 
± 14 minutes and 54 ± 24 minutes respectively, 
including 45 patients who underwent surgery 
through ministernotomy. Concomitant coronary 
bypass was done in 48 patients. Mean 
preoperative and postoperative gradients were 
48.6 ±18.6 mm Hg and 10.4 ± 4.3 mm Hg, 
respectively, and preoperative and 
postoperative mean effective orifice areas were 
0.7 ± 0.2 and 1.4 ± 0.4 cm2. Survival at 12 
months was 87.1%, success of implantation was 
95%, and freedom from reoperation was 96%. In 
hospital mortality was 2.4%. During follow-up, 9 
patients (4%) required reoperation for 
paravalvular regurgitation; 7 early and 2 late 
reoperations. 
 The authors concluded that Perceval 
sutureless is a safe bioprosthesis that can easily 
be implanted, including though a minimally 
invasive technique. Mid-term hemodynamics are 
very satisfying with significant clinical 
improvement. 
TECHNIQUE OF IMPLANTATION 
 The procedure is performed through 
median sternotomy and usual exposure of the 
cardiac structures or through upper right mini-
sternotomy. The aorta is cannulated as high as 
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possible to allow a transverse aortotomy 
approximatively 3 to 3.5 cm above the expected 
level of the aortic anulus. Excision of the leaflets 
is performed in a standard fashion as the 
removal of irregular protruding anular 
calcifications. Basically there is no need to 
decalcify the annulus itself. Three guiding 
sutures are placed below the aortic annulus at 
the nadir of each sinus. Sizing of the annulus is 
performed with dedicated universal sizers (in the 
commercial phase they will be named as S-M-L-
XL). The device is prepared on a side table by 
collapsing it (not crimping), and is mounted on 
dedicated delivery device. Guiding sutures are 
passed within the loops present on the external 
aspect of the inflow ring and the device can be 
now parachuted into the root. The guiding 
sutures assure correct alignment and prevent 
too low positioning into the LVOT.  Correct intra-
anular positioning is checked before final release 
and is facilitated due to optimal visualization and 
low profile of the delivery device. The inflow and 
the outflow are released sequentially, the 
guiding sutures are removed. Final sealing is 
assured by dedicated balloon-dilation at 4 
atmospheres for 30” under direct vision. Finally 
the aortotomy is closed as per routine. 
 
 
Figure 12. Valve to be collapsed (left) and ready for implantation (right) 
 
Figure 13. The guiding stitches are passed through the corresponding loops present at the external aspect of the 
inflow ring (left). The valve has been parachuted into position (right). 
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Figure 14.  Final step of the implantation: dilatation of 
the Perceval S valve into the aortic annulus. 
CURRENT STUDY 
 On the basis of the Pilot results and 
preliminary outcomes of the Pivotal study, Sorin 
Biomedica Cardio S.r.l. planned the CAVALIER 
study designed to evaluate the safety and 
effectiveness of the Perceval S valve with 
extended indications in terms of age (≥ 65 years) 
and valve sizes (21-23-25). A minimum of 300 
patients will have been enrolled and followed to 
a minimum of 1 year post-implant. As necessary, 
additional patients will be implanted and 
followed until the requirement of 800 valve-
years of experience is achieved. The primary 
endpoint is the evaluation of the safety and 
effectiveness (in terms of improvement of 
clinical status and hemodynamic performance) 
of the Perceval S valve at 12 months after 
implant, while the secondary endpoints are the 
assessment of mortality and morbidity rates and 
of the effectiveness at discharge and at 3-6 
months follow-up. The study started in February 
2010 and at present the patients enrolment is 
still currently ongoing in 25 European 
Investigational Centers with 317 patients 
implanted.  
 According to the larger present experience 
in more centers than in the pilot study, the 
Perceval S sutureless bioprosthesis is user-
friendly and has a low profile device. 
Implantation can be performed easily after a 
short learning curve, even in small and/or 
calcified aortic roots. The procedure is facilitated 
because sutures are not required and the 
deployment starts from a completely collapsed 
prosthesis. In the present experience, the 
Perceval S system allowed for at least 50% 
reduction of aortic cross-clamp time, the 
shortest clamping time being around 15 to 18 
minutes.  This may have a positive impact on 
post-operative outcomes, especially if pre-
operative conditions are border-line (severe 
COPD / renal dysfunction), or  in older age 
patients as well as in situations where 
concomitant procedures are needed (CABG, AFib 
ablation, PFO closure and others). Clinical 
proven durability at 4 years, since more than 500 
pts already operated upon since 2007, and 
predicate device and lab tests show promising 
long-term durability. 
EXPERIMENTAL TRANSAPICAL 
IMPLANTATION OF THE PERCEVAL S 
VALVE  
 Transapical aortic valve implantation 
offers the possibility to deploy a prosthetic aortic 
valve mounted on a stent in accordance with 
these principles. The antegrade approach to the 
aortic valve through the left ventricular apex is 
particularly helpful when there is significant 
occlusive disease and/or calcification of the 
aorto-iliac bifurcation, and in case of heavy 
calcification of the ascending aorta (porcelain 
aorta) the transapical valve insertion may 
diminish the risk of stroke. 
 The main currently available transapical 
device is the Edwards Sapien valve, while the 
CoreValve prosthesis has been used occasionally 
for transapical valve implantation [55, 56]. The 
procedure relies on an ability to anchor the valve 
within the native aortic valve calcification, using 
radial force to prevent retrograde slippage or 
distal embolization. The most dreaded 
complication of transcatheter implantation of an 
aortic valve following balloon dilation relates to 
the embolization of calcific debris from the 
native aortic valve. 
 Off-pump transapical aortic valve 
implantation was performed through a left 
minithoracotomy using a bovine pericardial 
valve mounted on a self-expandable nitinol stent 
of size 21 mm and 23 mm in 11 pigs (average 
weight 60 kg). The collapsed valve was 
introduced through the left ventricular apex 
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using a flexible and steerable delivery sheath, 
using a three-step technique. Biplane 
fluoroscopy and transesophageal 
echocardiography were simultaneously used for 
guidance. Successful adjustment of alignment 
along three axes prior to deployment of the 
valve was accomplished in each animal. 
Deployments were performed during a period of 
rapid pacing. 
 All valves were successfully deployed and 
functioned normally following transapical 
removal of the delivery system. Paravalvular leak 
was documented in one case (9.1%) due to 
prosthetic misalignment. There was no evidence 
of valve migration. Correct anatomic seating was 
confirmed during post-procedure necropsy. 
Successful transapical implantation of this novel 
self-expandable bovine pericardial valve was 
accomplished in 11 animals, without 
cardiopulmonary bypass. A flexible, steerable 
delivery system with a three-step release 
mechanism allowed precise positioning of the 
valve with a low rate of paravalvular leakage, 
and excellent device stability. 
 The implantation of an expandable aortic 
valve prosthesis via the left ventricular apex 
currently relies upon an ability to anchor the 
prosthesis within the native leaflet calcium. 
Whilst successful in the majority of patients, this 
relatively new procedure unfortunately leaves 
the diseased native valve in place, exposing the 
patient to the potential risk for distal 
embolization of either calcific debris or the 
prosthesis itself [57]. Furthermore, the long-
term impact of residual paravalvular leakage due 
to deployment within an irregular annular 
circumference is unknown. The Perceval valve 
addresses these potential limitations, allowing 
deployment of the prosthesis within a circular 
orifice, and optimal adaptation to the native 
aortic sinus dimensions. The three-step 
deployment mechanism allows a controlled 
release process of the valve, guided both by 
aortic root angiography and TEE. The initial 
results of transapical deployment in a pig model 
.revealed that the technique was safe and 
reproducible. 
 The ideal design for the transapical 
catheter delivery of a biological valve should aim 
at removal of the native valve, followed by 
sutureless prosthetic replacement. This strategy 
would be close to the ‘gold standard’ 
represented by the conventional prosthetic 
valve replacement that has been performed 
routinely for the past four decades. Strategies 
for the transapical resection of native aortic 
valve tissue have been examined and reported 
[58-61]. For example, a sophisticated method of 
in-situ transluminal resection of aortic valve 
leaflets using a YAG laser within an aortic valve 
isolation chamber has been developed. In a 
retrograde cadaver model, it was shown that 
each cusp could be resected with an average 
time of 6 minutes. The most recent report from 
this group compared the antegrade and 
retrograde approaches, and demonstrated that 
‘fewer severe lesions’ occurred in the aorta 
when using a transapical antegrade approach 
compared to the transluminal retrograde 
strategy [62]. Salizzoni and colleagues, from the 
University of Pittsburgh, have recently shown 
that a percutaneous removal of the aortic valve 
is possible off-pump in animals [63]. The new 
design of the Perceval valve, combined with the 
pericardial inflow skirt, are most likely 
responsible for the impressive freedom from 
paravalvular leakage reported in humans to 
date. This contrasts with all other clinically 
available transcatheter valve procedures using 
various prostheses [64]. Furthermore, the ability 
to crimp the device for transapical or 
transfemoral delivery makes it very attractive 
[65]. While the first-generation Cribier-Edwards 
prosthesis utilized equine pericardium, the 
current version CoreValve leaflets are composed 
of porcine pericardium, the late durability of 
which has not been evaluated in humans [66]. 
Other valve prostheses use bovine pericardium, 
which has been employed in stented valves for 
over two decades, and an initial clinical 
experience with the Ventor Embracer (Ventor 
Technogies, Netanya, Israel) was recently 
published [67]. This is a bovine pericardial valve 
with a selfexpanding nitinol stent and three 
support arms that are lodged in the aortic 
sinuses, so as to allow self-centering and both 
axial and radial forces for stabilization. The 
Perceval valve is based on the bovine pericardial 
Sorin bioprosthesis which has been used 
clinically since 1985, and has a well-documented 
performance [68, 69]. 
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THE INTUITY SUTURELESS VALVE 
FROM EDWARDS 
 The Edwards Intuity valve system 
leverages a proven valve platform and features 
an innovative balloon-expandable frame for 
rapid deployment. The bovine pericardial tissue 
used for construction of this valve is treated by 
Thermafix process which is similar to that 
already used for the stented Permount valves 
from the same company. The Intuity sutureless 
valve includes a broad polyester sealing cloth to 
be expanded at the level and slightly below the 
native aortic valve anulus which covers the 
balloon expandable stainless steel frame (Figures 
15 and 16).  
 
Figure 15. The Intuity sutureless valve (courtesy from 
Edwards) 
 
Figure 16. The large polyester cuff of the Intuity valve 
ensures optimal sealing at the level       of the anulus 
and just below (courtesy from Edwards) 
 In the prospective, single-arm TRITON trial, 
six European centres treated 152 consecutive 
patients in need of surgical aortic valve 
replacement [70]. Procedural success was 97.3%. 
Surgeons performed 86 isolated aortic valve 
replacement procedures, with about half of 
these cases using small-incision approaches. 
Mean EOA and gradients were 1.7± 0.1 cm2 and 
8.4 ± 0.7 mm Hg at three months and remained 
unchanged at one-year follow-up. All data were 
adjudicated by a clinical event committee and 
were Echocardiography Core Lab reviewed.The 
immediate incidence of paravalvular leaks was 
low. Valve-related mortality rates were low in 
the mid-term; survival in this group of patients 
was 98.6% at 30 days and, at one year, the 
Kaplan-Meier curve demonstrated 94% freedom 
from death. 
 The data also demonstrated shortened 
procedures, as characterised by acceptably short 
cross-clamp times and times spent on 
cardiopulmonary bypass. For isolated aortic 
valve replacement cases, mean aortic cross-
clamp times were reduced by 48%, and mean 
bypass times by 39%, compared to times noted 
in the Society of Thoracic Surgeons’ Adult 
Cardiac Database. 
 The study gave the authors confidence in 
the opportunity to use this system with less-
invasive surgical approaches. The overall 
performance of the Edwards Intuity valve system 
is promising, due to the early excellent 
haemodynamic results and the design inspired 
by the proven platform of Edwards’ family of 
surgical valves. The Edwards Intuity valve system 
received CE mark in Europe in February 2012. 
STUDY SUMMARY 
 Although attractive, a strategy of valve 
excision before prosthesis implantation still 
relies on an ability to resect the native aortic 
valve, and to implant a new prosthesis while 
maintaining hemodynamic stability. The 
optimization of catheter-based resection 
techniques will be necessary before this can be 
achieved. However, in the less-frequent 
conditions leading to aortic insufficiency with 
thin pliable leaflets and a preserved aortic root 
anatomy, (e.g. endocarditis, perforation), valve 
resection would not be necessary. Finally, the 
ability to place the aortic root sinus-conforming 
stent against the aortic wall relies on the 
absence of aortic root or ascending aortic 
dilatation. In conclusion, transapical 
implantation of the Perceval self-expanding 
bovine pericardial valve without CPB is 
technically feasible and safe. A flexible, steerable 
delivery system with a three-step release 
mechanism allows for a precise positioning of 
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the valve, with a very low rate of paravalvular 
leakage and excellent device stability. The 
preliminary results of this trial will hopefully re-
energize the search for strategies to perform 
native valve resection, and thereby facilitate the 
clinical introduction of truly minimally invasive 
transapical aortic valve replacement. 
CONCLUSIONS 
 Presently three different types of 
sutureless valve are available on the market with 
distinct designs and different deployment 
techniques. The definitive clinical use is difficult 
to predict but these valves may become 
substitutes for all conventional stented and 
stentless biological valves; in addition these 
valves have a potential for breakthrough of 
minimal access surgery since they may facilitate 
valve replacement through such approaches. 
Finally the more the use and deployment of 
sutureless valves will be simplified, the more a 
broad surgical community will adopt this new 
technology. Today it remains difficult to predict 
which patients may be the best candidates for 
sutureless valve implantation and in which ones 
a maximal benefit would be observed. 
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